138 related articles for article (PubMed ID: 25264128)
1. Activity of the investigational fluoroquinolone finafloxacin and seven other antimicrobial agents against 114 obligately anaerobic bacteria.
Genzel GH; Stubbings W; Stîngu CS; Labischinski H; Schaumann R
Int J Antimicrob Agents; 2014 Nov; 44(5):420-3. PubMed ID: 25264128
[TBL] [Abstract][Full Text] [Related]
2. Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents.
Peric M; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Aug; 48(8):3188-92. PubMed ID: 15273148
[TBL] [Abstract][Full Text] [Related]
3. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients.
Edmiston CE; Krepel CJ; Kehl KS; Seabrook GR; Somberg LB; Almassi GH; Smith TL; Loehrl TA; Brown KR; Lewis BD; Towne JB
J Antimicrob Chemother; 2005 Nov; 56(5):872-8. PubMed ID: 16186167
[TBL] [Abstract][Full Text] [Related]
5. Comparative antianaerobic activity of BMS 284756.
Hoellman DB; Kelly LM; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2001 Feb; 45(2):589-92. PubMed ID: 11158759
[TBL] [Abstract][Full Text] [Related]
6.
Kong Y; Li C; Li G; Yang T; Draz MS; Xie X; Zhang J; Ruan Z
Microbiol Spectr; 2022 Jun; 10(3):e0009922. PubMed ID: 35532225
[TBL] [Abstract][Full Text] [Related]
7. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria.
Ackermann G; Schaumann R; Pless B; Claros MC; Goldstein EJ; Rodloff AC
Eur J Clin Microbiol Infect Dis; 2000 Mar; 19(3):228-32. PubMed ID: 10795599
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activity of finafloxacin against staphylococci displaying normal and small colony variant phenotypes.
Idelevich EA; Kriegeskorte A; Stubbings W; Kahl BC; Peters G; Becker K
J Antimicrob Chemother; 2011 Dec; 66(12):2809-13. PubMed ID: 21948963
[TBL] [Abstract][Full Text] [Related]
9. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
Aldridge KE
Antimicrob Agents Chemother; 1994 Jul; 38(7):1671-4. PubMed ID: 7979307
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of 497 clinical isolates of gram-negative anaerobes to trovafloxacin and eight other antibiotics.
Rotimi VO; Mokaddas EM; Jamal WY; Khodakhast FB; Verghese TL; Sanyal SC
J Chemother; 1999 Oct; 11(5):349-56. PubMed ID: 10632380
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.
Nord CE
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101
[TBL] [Abstract][Full Text] [Related]
12. ["In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002].
Litterio M; Bianchini H; Carloni G; Di Martino A; Fernández Canigia L; Greco G; Legaria C; Rollet R; Rossetti A; Predari SC; Castello L
Rev Argent Microbiol; 2004; 36(3):130-5. PubMed ID: 15559195
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria.
Venezia RA; Yocum DM; Robbiano EM; Echols RM
Antimicrob Agents Chemother; 1990 Sep; 34(9):1858-61. PubMed ID: 2178340
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of three of the newer quinolones against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Antimicrob Agents Chemother; 1992 Jan; 36(1):239-43. PubMed ID: 1317149
[TBL] [Abstract][Full Text] [Related]
15. [Use of the Etest method for antimicrobial susceptibility testing of obligate anaerobes].
Rokosz A; Sawicka-Grzelak A; Kot K; Meszaros J; Łuczak M
Med Dosw Mikrobiol; 2001; 53(2):167-75. PubMed ID: 11757426
[TBL] [Abstract][Full Text] [Related]
16. Multicenter study of antimicrobial susceptibility of anaerobic bacteria in Korea in 2012.
Lee Y; Park YJ; Kim MN; Uh Y; Kim MS; Lee K
Ann Lab Med; 2015 Sep; 35(5):479-86. PubMed ID: 26206683
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of anaerobic bacteria to PD 131628.
Nord CE; Hagelbäck A
Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):68-71. PubMed ID: 1314176
[TBL] [Abstract][Full Text] [Related]
18. Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila.
Lemaire S; Van Bambeke F; Tulkens PM
Int J Antimicrob Agents; 2011 Jul; 38(1):52-9. PubMed ID: 21596526
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.
Nord CE; Lindmark A; Persson I
Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):640-2. PubMed ID: 8223667
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections.
Odou MF; Muller C; Calvet L; Dubreuil L
J Antimicrob Chemother; 2007 Apr; 59(4):646-51. PubMed ID: 17350985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
